Skip to main content
ARTL
NASDAQ Life Sciences

Artelo Biosciences Adjourns Annual Meeting Due to Lack of Quorum, Reschedules for January 30

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$1.27
Mkt Cap
$2.564M
52W Low
$1.15
52W High
$28.6
52W Position info
10% above low
Off High info
96% below high
Rel. Volume
Market data snapshot near publication time

ARTL is trading near its 52-week low of $1.15 (10% above the low).

Summary

Artelo Biosciences adjourned its 2025 annual meeting of stockholders due to insufficient votes for a quorum, rescheduling it for January 30, 2026, and plans to add a proposal for auditor ratification.


Key Events · Corporate Governance and Compliance · ARTL

  • Annual Meeting Adjourned

    The 2025 annual meeting of stockholders was adjourned on December 31, 2025, without conducting any business, due to insufficient votes to constitute a quorum.

  • Meeting Rescheduled

    The Annual Meeting will reconvene virtually on Friday, January 30, 2026, at 8:00 a.m. Pacific Time, to allow stockholders additional time to vote.

  • New Proposal Anticipated

    An additional proposal to ratify the appointment of Malone Bailey LLP as the independent auditor for the fiscal year ending December 31, 2026, is expected to be added to the agenda.


Analysis · ARTL · Life Sciences

Artelo Biosciences' inability to achieve a quorum for its annual meeting is a notable governance concern, particularly for a micro-cap company. This suggests low shareholder engagement or potential challenges in securing votes for its proposals. The rescheduling provides additional time for shareholders to vote, and the anticipated addition of an auditor ratification proposal is a standard item for annual meetings. Investors should monitor the reconvened meeting to see if quorum is met and how proposals are voted on, as continued difficulty could signal deeper governance or shareholder relations issues.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ARTL was trading at $1.27 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.6M. The 52-week trading range was $1.15 to $28.60. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ARTL - Latest Insights

ARTL
Nov 12, 2026, 8:00 AM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $2.24
Real-time Price: $1.39 info
Change: -$0.850 (-38%) info
Market Cap: $1.303M info
ARTL
Oct 09, 2026, 5:15 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $3.19
Real-time Price: $1.39 info
Change: -$1.80 (-56%) info
Market Cap: $1.303M info
ARTL
Sep 23, 2026, 1:46 PM EDT
Source: Benzinga
Importance Score:
8
Price at Filing: $7.84
Real-time Price: $1.39 info
Change: -$6.45 (-82%) info
Market Cap: $1.303M info
ARTL
Sep 16, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $5.02
Real-time Price: $1.39 info
Change: -$3.63 (-72%) info
Market Cap: $1.303M info
ARTL
Aug 27, 2026, 8:30 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.658
Real-time Price: $1.39 info
Change: Reverse Stock Split info
Market Cap: $1.303M info